NasdaqGM:VNDABiotechs
Vanda Pharmaceuticals (VNDA) Is Up 33.8% After FDA Approval Of BYSANTI Atypical Antipsychotic
Vanda Pharmaceuticals recently received U.S. FDA approval for BYSANTI (milsaperidone) tablets, a new atypical antipsychotic for acute manic or mixed episodes in bipolar I disorder and for schizophrenia in adults, with U.S. commercial launch targeted for the third quarter of 2026 and marketing protection expected into 2044.
BYSANTI’s status as a new chemical entity that rapidly converts to iloperidone, aligning with Fanapt’s established safety profile while offering dual active molecules,...